Anaphylaxis
Risk of severe allergic reaction. Seek urgent medical help if serious symptoms occur.
Medicine information SARCLISA 20mg / ml concentrate for oral solution
- Product code:
- W66955002
- Quantity:
- 3
- Indicated for:
- cancer
- Route of administration:
- oral
- Substance:
- isatuximab (monoclonal antibody)
- ATC
- L01FC02 — Antineoplastic and immunomodulating agents | Monoclonal antibodies and antibody drug conjugates | Cd38 (clusters of differentiation 38) inhibitors
Isatuximab is a monoclonal antibody used to treat relapsed or refractory multiple myeloma in adult patients. It works by binding to the CD38 protein on the surface of myeloma cells, activating the immune system to destroy cancer cells.
The medication is administered intravenously, usually in combination with other drugs, under the supervision of an oncologist.
Side effects may include fatigue, nausea, diarrhea, decreased blood cell counts, or infusion-related reactions. In rare cases, severe allergic reactions may occur.
Patients should be closely monitored during treatment and inform their doctor about any other medications they are taking. Pregnant or breastfeeding women should consult a specialist before use.
The medication is administered intravenously, usually in combination with other drugs, under the supervision of an oncologist.
Side effects may include fatigue, nausea, diarrhea, decreased blood cell counts, or infusion-related reactions. In rare cases, severe allergic reactions may occur.
Patients should be closely monitored during treatment and inform their doctor about any other medications they are taking. Pregnant or breastfeeding women should consult a specialist before use.
General data about SARCLISA 20mg / ml
- Substance:
- isatuximab
- Date of latest medicines list:
- 01-04-2026
- Product code:
- W66955002
- Strength:
- 20mg / ml
- Pharmaceutical form:
- concentrate for oral solution
- Quantity:
- 3
- Product type:
- Original
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Pharmaceutical forms available for isatuximab
Official documents
The SmPC text is not displayed because a match to this medicine, strength and pharmaceutical form has not been confirmed.
The correspondence between the document and the displayed text is unconfirmed.
- Source institution
- EMA
- Document language
- English
- Source record: first published
- 12/06/2020
- Source record: last updated
- 07/07/2026
Warnings:
Additional monitoring
This medicine is subject to additional monitoring.
Breastfeeding warning
Use during breastfeeding only on medical advice.
Pregnancy warning
Use during pregnancy only on medical advice.